FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic cancerCONROY, T; DESSEIGNE, F; BENNOUNA, J et al.Cancéro digest. 2011, Vol 3, Num 4, pp 310-312, issn 1953-5171, 3 p.Article

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)DUCREUX, M; ADENIS, A; CONROY, T et al.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1236-1245, issn 0959-8049, 10 p.Article

A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le CancerBECOUARN, Y; SENESSE, P; THEZENAS, S et al.Annals of oncology. 2007, Vol 18, Num 12, pp 2000-2005, issn 0923-7534, 6 p.Article